• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ainos, Inc. - warrants (NQ:AIMDW)

0.1034 -0.0055 (-5.05%)
Streaming Delayed Price Updated: 3:47 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ainos, Inc. - warrants

< Previous 1 2 3 4 5 Next >
News headline image
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
September 24, 2024
Via ACCESSWIRE
News headline image
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
September 23, 2024
Via ACCESSWIRE
News headline image
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
September 20, 2024
Via ACCESSWIRE
News headline image
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
September 17, 2024
Via ACCESSWIRE
News headline image
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
September 03, 2024
Via ACCESSWIRE
News headline image
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
Via ACCESSWIRE
News headline image
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter
August 26, 2024
Via ACCESSWIRE
News headline image
Ainos Reports Second Quarter 2024 Financial Results
August 05, 2024
Via ACCESSWIRE
News headline image
Ainos Reports First Quarter 2024 Financial Results
May 13, 2024
Via ACCESSWIRE
News headline image
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
August 19, 2024
Via ACCESSWIRE
News headline image
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024
August 12, 2024
Via ACCESSWIRE
News headline image
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
August 09, 2024
Via ACCESSWIRE
News headline image
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
June 13, 2024
Via ACCESSWIRE
News headline image
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
May 07, 2024
Via ACCESSWIRE
News headline image
Ainos Reports Full Year 2023 Financial Results
March 08, 2024
Via ACCESSWIRE
News headline image
Ainos Announces $1.75 Million Follow-On Funding
January 24, 2024
Via ACCESSWIRE
News headline image
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
November 28, 2023
Via ACCESSWIRE
News headline image
Ainos Reports Third Quarter 2023 Financial Results
November 09, 2023
Via ACCESSWIRE
News headline image
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
September 25, 2023
Via ACCESSWIRE
News headline image
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
February 05, 2024
Via ACCESSWIRE
News headline image
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
February 01, 2024
Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 02, 2024
Via ACCESSWIRE
News headline image
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
December 26, 2023
Via ACCESSWIRE
News headline image
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
September 05, 2023
Via ACCESSWIRE
News headline image
Ainos Reports Second Quarter 2023 Financial Results
August 11, 2023
Via ACCESSWIRE
News headline image
Ainos Celebrates First Listing Anniversary on Nasdaq
August 10, 2023
Via ACCESSWIRE
News headline image
Ainos, Inc. Announces Stock Consolidation
December 12, 2023
Via ACCESSWIRE
News headline image
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
November 21, 2023
Via ACCESSWIRE
News headline image
Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
September 18, 2023
Via ACCESSWIRE
News headline image
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption
August 09, 2023
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap